TISSIUM, a private medtech specialising in the development of programmable biomorphic polymers for tissue reconstruction, announces it has obtained a non-dilutive financing of €4.2 million from Bpifrance as part of the France 2030 plan to extend its production capacity for large volume syringes.
Number1411 Shutterstock
530884738
Double exposure of graph and rows of coins for finance and business concept
TISSIUM is developing a portfolio of products that leverage its proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are the foundation of the company’s technology platform. Currently, the company has a pipeline of seven products across three verticals, including atraumatic sutureless nerve repair, hernia repair and cardiovascular sealants. Each product is designed to enhance the tissue reconstruction process in a unique way. In addition, the company develops complementary delivery and activation devices for enhanced performance and usability of its products.
Christophe Bancel, CEO of TISSIUM, commented: “This new financing demonstrates the confidence of the French State in the solidity of our project and the potential of our solutions. It will allow us to rapidly increase our production capacity, but also help us enrich our platform. We will thus be able to meet the demand of surgeons and allow a large number of patients to benefit from our products once they are approved by the regulatory authorities. This will also contribute to the reindustrialisation and the development of employment in France”.
TISSIUM’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013.